We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Johnson & Johnson (JNJ) Q4 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts forecast that Johnson & Johnson (JNJ - Free Report) will report quarterly earnings of $2.50 per share in its upcoming release, pointing to a year-over-year increase of 22.6%. It is anticipated that revenues will amount to $24.14 billion, exhibiting an increase of 7.2% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Johnson & Johnson metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Sales- Innovative Medicine- WW' should arrive at $15.42 billion. The estimate points to a change of +7.6% from the year-ago quarter.
The consensus estimate for 'Sales- MedTech- Total' stands at $8.71 billion. The estimate points to a change of +6.4% from the year-ago quarter.
Analysts forecast 'Sales- MedTech- Orthopaedics- Trauma- WW' to reach $795.14 million. The estimate indicates a change of +4.1% from the prior-year quarter.
Analysts' assessment points toward 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW' reaching $735.66 million. The estimate suggests a change of +0.1% year over year.
Analysts expect 'Sales- Innovative Medicine- Oncology- CARVYKTI- WW' to come in at $624.42 million. The estimate suggests a change of +87% year over year.
Analysts predict that the 'Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW' will reach $463.39 million. The estimate indicates a change of +56% from the prior-year quarter.
The average prediction of analysts places 'Sales- MedTech- Cardiovascular- Other Cardiovascular- WW' at $103.51 million. The estimate indicates a year-over-year change of +4.6%.
The collective assessment of analysts points to an estimated 'Sales- MedTech- Cardiovascular- ABIOMED- WW' of $446.56 million. The estimate indicates a change of +16.3% from the prior-year quarter.
The consensus among analysts is that 'Sales- International' will reach $10.14 billion. The estimate indicates a year-over-year change of +8.9%.
According to the collective judgment of analysts, 'Sales- MedTech- Cardiovascular- Electrophysiology- WW' should come in at $1.48 billion. The estimate indicates a change of +12.1% from the prior-year quarter.
It is projected by analysts that the 'Sales- MedTech- Orthopaedics- Hips- US' will reach $278.24 million. The estimate indicates a change of +2.3% from the prior-year quarter.
The combined assessment of analysts suggests that 'Organic Sales Growth (Operational growth)' will likely reach 6.1%. Compared to the current estimate, the company reported 6.7% in the same quarter of the previous year.
Johnson & Johnson shares have witnessed a change of +3.9% in the past month, in contrast to the Zacks S&P 500 composite's +1.6% move. With a Zacks Rank #3 (Hold), JNJ is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Johnson & Johnson (JNJ) Q4 Earnings, Beyond Revenue and EPS
Wall Street analysts forecast that Johnson & Johnson (JNJ - Free Report) will report quarterly earnings of $2.50 per share in its upcoming release, pointing to a year-over-year increase of 22.6%. It is anticipated that revenues will amount to $24.14 billion, exhibiting an increase of 7.2% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Johnson & Johnson metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Sales- Innovative Medicine- WW' should arrive at $15.42 billion. The estimate points to a change of +7.6% from the year-ago quarter.
The consensus estimate for 'Sales- MedTech- Total' stands at $8.71 billion. The estimate points to a change of +6.4% from the year-ago quarter.
Analysts forecast 'Sales- MedTech- Orthopaedics- Trauma- WW' to reach $795.14 million. The estimate indicates a change of +4.1% from the prior-year quarter.
Analysts' assessment points toward 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW' reaching $735.66 million. The estimate suggests a change of +0.1% year over year.
Analysts expect 'Sales- Innovative Medicine- Oncology- CARVYKTI- WW' to come in at $624.42 million. The estimate suggests a change of +87% year over year.
Analysts predict that the 'Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW' will reach $463.39 million. The estimate indicates a change of +56% from the prior-year quarter.
The average prediction of analysts places 'Sales- MedTech- Cardiovascular- Other Cardiovascular- WW' at $103.51 million. The estimate indicates a year-over-year change of +4.6%.
The collective assessment of analysts points to an estimated 'Sales- MedTech- Cardiovascular- ABIOMED- WW' of $446.56 million. The estimate indicates a change of +16.3% from the prior-year quarter.
The consensus among analysts is that 'Sales- International' will reach $10.14 billion. The estimate indicates a year-over-year change of +8.9%.
According to the collective judgment of analysts, 'Sales- MedTech- Cardiovascular- Electrophysiology- WW' should come in at $1.48 billion. The estimate indicates a change of +12.1% from the prior-year quarter.
It is projected by analysts that the 'Sales- MedTech- Orthopaedics- Hips- US' will reach $278.24 million. The estimate indicates a change of +2.3% from the prior-year quarter.
The combined assessment of analysts suggests that 'Organic Sales Growth (Operational growth)' will likely reach 6.1%. Compared to the current estimate, the company reported 6.7% in the same quarter of the previous year.
View all Key Company Metrics for Johnson & Johnson here>>>Johnson & Johnson shares have witnessed a change of +3.9% in the past month, in contrast to the Zacks S&P 500 composite's +1.6% move. With a Zacks Rank #3 (Hold), JNJ is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .